More recently, genes targeted through activation of ROR1 signaling (e.g., ERK1/2 or NF-κB target genes) have been defined [19, 21], including the BCL2L1 gene encoding BCL-XL, which may enhance resistance to venetoclax in CLL or mantle-cell-lymphoma [25–28]. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.